Breast cancer is one of the most common cancers and the leading cause of cancer-related deaths among women due to the diagnostic delay and failure of treatment.1 Despite the significant progress made in developing the...Breast cancer is one of the most common cancers and the leading cause of cancer-related deaths among women due to the diagnostic delay and failure of treatment.1 Despite the significant progress made in developing therapeutic strategies for breast cancer,effective treatment of breast cancer,particularly aggressive triple-negative breast cancer,remains lacking.Angiogenesis is a crucial risk factor for breast cancer metastasis and a predictor of poor prognosis.Thus,developing novel agents capable of suppressing tumor angiogenesis offers a promising approach for breast cancer treatment.Oridonin,the major active ingredient of the traditional Chinese medicinal herb,exhibits anti-cancer activity by inhibiting tumor-induced angiogenesis.2 Nevertheless,the therapeutic potential of oridonin is limited due to its rapid plasma clearance and limited potency.Various novel oridonin analogues have been designed and chemically synthesized by modifying their A,B,and D rings to achieve an agent with better anti-cancer efficacy and lower toxicity than oridonin.3 Chick embryo chorioallantoic membrane(CAM)and yolk sac membrane(YSM)models were commonly utilized to study tumor-induced angiogenesis.To discover the promising anti-angiogenic agents,we screened novel oridonin analogues synthesized in-house using the CAM and YSM models.展开更多
基金supported by the Basic and Applied Basic Research Project of Guangdong Province,China(No.2023A1515010459 to C.L.Q.)Key Team of Basic and Clinical Research on Tumor Immunotherapy of Guangdong Pharmaceutical University(No.2024ZZ10 to X.L.)+2 种基金the Project of Administration of Traditional Chinese Medicine of Guangdong Province,China(No.20251209 to C.L.Q.20242048 to P.T.)Dr.Jia Zhou has no connections with the above-mentioned funding resources in China,and is partly supported by the John D.Stobo,M.D.Distinguished Chair Endowment Fund,and Edith&Robert Zinn Chair in Drug Discovery Endowment Fund at the University of Texas Medical Branch in the United States.
文摘Breast cancer is one of the most common cancers and the leading cause of cancer-related deaths among women due to the diagnostic delay and failure of treatment.1 Despite the significant progress made in developing therapeutic strategies for breast cancer,effective treatment of breast cancer,particularly aggressive triple-negative breast cancer,remains lacking.Angiogenesis is a crucial risk factor for breast cancer metastasis and a predictor of poor prognosis.Thus,developing novel agents capable of suppressing tumor angiogenesis offers a promising approach for breast cancer treatment.Oridonin,the major active ingredient of the traditional Chinese medicinal herb,exhibits anti-cancer activity by inhibiting tumor-induced angiogenesis.2 Nevertheless,the therapeutic potential of oridonin is limited due to its rapid plasma clearance and limited potency.Various novel oridonin analogues have been designed and chemically synthesized by modifying their A,B,and D rings to achieve an agent with better anti-cancer efficacy and lower toxicity than oridonin.3 Chick embryo chorioallantoic membrane(CAM)and yolk sac membrane(YSM)models were commonly utilized to study tumor-induced angiogenesis.To discover the promising anti-angiogenic agents,we screened novel oridonin analogues synthesized in-house using the CAM and YSM models.
